Filing Flows › Bristol Myers Squibb (BMY) › Q3 2026 › vs Q3 2025
Bristol Myers Squibb (BMY) Q3 2026 vs Q3 2025 (year over year)
Bristol Myers Squibb's revenue rose $847M (+7%) from $12.2B in Q3 2025 to $13.1B in Q3 2026. The biggest changes: Net product sales +$1.4B (+13%); Camzyos +$124M (+42%). Operating margin 19.4% against 25.5% (-6.1 pts).
Bristol Myers Squibb, Q3 2026: revenue $13.1B (+7% year over year), operating margin 19.4%, net earnings $2.2B, operating cash flow $4.2B. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Operating margin | 19.4% | 25.5% | -6.1 pts |
| Net margin | 16.5% | 18.0% | -1.4 pts |
| Free cash flow margin | 29.4% | 49.0% | -19.7 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Legacy Portfolio | $5.4B | $5.4B | $50.0M | +0.9% |
| Eliquis | $4.7B | $3.7B | $944M | +25% |
| Yervoy | $793M | $739M | $54.0M | +7% |
| Reblozyl | $750M | $615M | $135M | +22% |
| Breyanzi | $526M | $359M | $167M | +47% |
| Alliance and other revenues | $463M | $372M | $91.0M | +24% |
| Net product sales | $12.6B | $11.2B | $1.4B | +13% |
| Camzyos | $420M | $296M | $124M | +42% |
| Revenue | $13.1B | $12.2B | $847M | +7% |
| Operating profit | $2.5B | $3.1B | −$578M | -19% |
| Costs & expenses | $10.5B | $9.1B | $1.4B | +16% |
| Pre-tax earnings | $2.5B | $3.1B | −$578M | -19% |
| Cost of revenue | $4.1B | $3.4B | $711M | +21% |
| Research & development | $2.4B | $2.5B | −$163M | -6% |
| SG&A | $1.7B | $1.8B | −$90.0M | -5% |
| Other operating costs | $2.3B | $1.4B | $967M | +71% |
| Net earnings | $2.2B | $2.2B | −$33.0M | -2% |
| Income tax | $374M | $919M | −$545M | -59% |
| Depreciation & amortization | $626M | $1.0B | −$385M | -38% |
| Share-based compensation | $138M | $139M | −$1.0M | -0.7% |
| Working capital & other | $1.3B | $3.0B | −$1.7B | -58% |
| Operating cash flow | $4.2B | $6.3B | −$2.1B | -34% |
| Free cash flow (OCF − capex) | $3.8B | $6.0B | −$2.2B | -36% |
| Capital expenditures | $344M | $320M | $24.0M | +7% |
Questions
How much did Bristol Myers Squibb's revenue grow year over year in Q3 2026?
Bristol Myers Squibb's revenue rose $847M (+7%) from $12.2B in Q3 2025 to $13.1B in Q3 2026.
What drove Bristol Myers Squibb's revenue change in Q3 2026?
Net product sales +$1.4B (+13%); Camzyos +$124M (+42%).